A Prospective Multi-center Trial of Escherichia coli Extract for the Prophylactic Treatment of Patients with Chronically Recurrent Cystitis
We have assessed the efficacy and safety of Escherichia coli extract (ECE; Uro-Vaxom) which contains active immunostimulating fractions, in the prophylactic treatment of chronically recurrent cystitis. Forty-two patients with more than 2 episodes of cystitis in the proceeding 6 months were treated f...
Saved in:
| Published in | Journal of Korean medical science Vol. 25; no. 3; pp. 435 - 439 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Korea (South)
The Korean Academy of Medical Sciences
01.03.2010
대한의학회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1011-8934 1598-6357 1598-6357 |
| DOI | 10.3346/jkms.2010.25.3.435 |
Cover
| Abstract | We have assessed the efficacy and safety of Escherichia coli extract (ECE; Uro-Vaxom) which contains active immunostimulating fractions, in the prophylactic treatment of chronically recurrent cystitis. Forty-two patients with more than 2 episodes of cystitis in the proceeding 6 months were treated for 3 months with one capsule daily of ECE and observed for a further 6 months. The primary efficacy criterion was the number of episodes of recurrent cystitis during the 6 months after treatment compared to those during the 6 months before treatment. At the end of the 9-month trial, 34 patients (all women) were eligible for statistical analysis. Their mean age was 56.4 yr (range, 34-75 yr), and they had experienced recurrent urinary tract infections for 7.2+/-5.2 yr. The number of recurrences was significantly lower during the 6-month follow-up period than during the 6 months preceding the trial (0.35 vs. 4.26, P<0.001). During the follow-up, 28 (82.4%) patients had no recurrences and 4 (11.8%) had 1 each. In patients who relapsed, ECE alleviated cystitis symptoms, including painful voiding, frequency and urgency. There were no serious adverse events related to the study drug. Our study demonstrates the efficacy and safety of ECE in the prophylactic treatment of chronically recurrent cystitis. |
|---|---|
| AbstractList | We have assessed the efficacy and safety of Escherichia coli extract (ECE; Uro-Vaxom®) which contains active immunostimulating fractions, in the prophylactic treatment of chronically recurrent cystitis. Forty-two patients with more than 2 episodes of cystitis in the proceeding 6 months were treated for 3 months with one capsule daily of ECE and observed for a further 6 months. The primary efficacy criterion was the number of episodes of recurrent cystitis during the 6 months after treatment compared to those during the 6 months before treatment. At the end of the 9-month trial, 34 patients (all women) were eligible for statistical analysis. Their mean age was 56.4 yr (range, 34-75 yr), and they had experienced recurrent urinary tract infections for 7.2±5.2 yr. The number of recurrences was significantly lower during the 6-month follow-up period than during the 6 months preceding the trial (0.35 vs. 4.26, P<0.001). During the follow-up, 28 (82.4%) patients had no recurrences and 4 (11.8%) had 1 each. In patients who relapsed, ECE alleviated cystitis symptoms, including painful voiding, frequency and urgency. There were no serious adverse events related to the study drug. Our study demonstrates the efficacy and safety of ECE in the prophylactic treatment of chronically recurrent cystitis. We have assessed the efficacy and safety of Escherichia coli extract (ECE; Uro-Vaxom) which contains active immunostimulating fractions, in the prophylactic treatment of chronically recurrent cystitis. Forty-two patients with more than 2 episodes of cystitis in the proceeding 6 months were treated for 3 months with one capsule daily of ECE and observed for a further 6 months. The primary efficacy criterion was the number of episodes of recurrent cystitis during the 6 months after treatment compared to those during the 6 months before treatment. At the end of the 9-month trial, 34 patients (all women) were eligible for statistical analysis. Their mean age was 56.4 yr (range, 34-75 yr), and they had experienced recurrent urinary tract infections for 7.2+/-5.2 yr. The number of recurrences was significantly lower during the 6-month follow-up period than during the 6 months preceding the trial (0.35 vs. 4.26, P<0.001). During the follow-up, 28 (82.4%) patients had no recurrences and 4 (11.8%) had 1 each. In patients who relapsed, ECE alleviated cystitis symptoms, including painful voiding, frequency and urgency. There were no serious adverse events related to the study drug. Our study demonstrates the efficacy and safety of ECE in the prophylactic treatment of chronically recurrent cystitis. We have assessed the efficacy and safety of Escherichia coli extract (ECE; Uro-Vaxom) which contains active immunostimulating fractions, in the prophylactic treatment of chronically recurrent cystitis. Forty-two patients with more than 2 episodes of cystitis in the proceeding 6 months were treated for 3 months with one capsule daily of ECE and observed for a further 6 months. The primary efficacy criterion was the number of episodes of recurrent cystitis during the 6 months after treatment compared to those during the 6 months before treatment. At the end of the 9-month trial, 34 patients (all women) were eligible for statistical analysis. Their mean age was 56.4 yr (range, 34-75 yr), and they had experienced recurrent urinary tract infections for 7.2+/-5.2 yr. The number of recurrences was significantly lower during the 6-month follow-up period than during the 6 months preceding the trial (0.35 vs. 4.26, P<0.001). During the follow-up, 28 (82.4%) patients had no recurrences and 4 (11.8%) had 1 each. In patients who relapsed, ECE alleviated cystitis symptoms, including painful voiding, frequency and urgency. There were no serious adverse events related to the study drug. Our study demonstrates the efficacy and safety of ECE in the prophylactic treatment of chronically recurrent cystitis.We have assessed the efficacy and safety of Escherichia coli extract (ECE; Uro-Vaxom) which contains active immunostimulating fractions, in the prophylactic treatment of chronically recurrent cystitis. Forty-two patients with more than 2 episodes of cystitis in the proceeding 6 months were treated for 3 months with one capsule daily of ECE and observed for a further 6 months. The primary efficacy criterion was the number of episodes of recurrent cystitis during the 6 months after treatment compared to those during the 6 months before treatment. At the end of the 9-month trial, 34 patients (all women) were eligible for statistical analysis. Their mean age was 56.4 yr (range, 34-75 yr), and they had experienced recurrent urinary tract infections for 7.2+/-5.2 yr. The number of recurrences was significantly lower during the 6-month follow-up period than during the 6 months preceding the trial (0.35 vs. 4.26, P<0.001). During the follow-up, 28 (82.4%) patients had no recurrences and 4 (11.8%) had 1 each. In patients who relapsed, ECE alleviated cystitis symptoms, including painful voiding, frequency and urgency. There were no serious adverse events related to the study drug. Our study demonstrates the efficacy and safety of ECE in the prophylactic treatment of chronically recurrent cystitis. We have assessed the efficacy and safety of Escherichia coli extract (ECE; Uro-Vaxom ) which contains active immunostimulating fractions, in the prophylactic treatment of chronically recurrent cystitis. Forty-two patients with more than 2 episodes of cystitis in the proceeding 6 months were treated for 3 months with one capsule daily of ECE and observed for a further 6 months. The primary efficacy criterion was the number of episodes of recurrent cystitis during the 6 months after treatment compared to those during the 6 months before treatment. At the end of the 9-month trial, 34 patients (all women) were eligible for statistical analysis. Their mean age was 56.4 yr (range, 34-75 yr), and they had experienced recurrent urinary tract infections for 7.2±5.2 yr. The number of recurrences was significantly lower during the 6-month follow-up period than during the 6 months preceding the trial (0.35 vs. 4.26, P<0.001). During the follow-up, 28 (82.4%) patients had no recurrences and 4 (11.8%) had 1 each. In patients who relapsed, ECE alleviated cystitis symptoms,including painful voiding, frequency and urgency. There were no serious adverse events related to the study drug. Our study demonstrates the efficacy and safety of ECE in the prophylactic treatment of chronically recurrent cystitis. KCI Citation Count: 4 |
| Author | Son, Hwancheol Jung, Hee Chang Choo, Myung-Soo Kim, Kun Suk Kim, Ji-Yoon Paick, Jae-Seung Park, Won Hee Shim, Hong Bang Lim, Dae Jung Jeong, In Gab |
| AuthorAffiliation | 2 Department of Urology, Seoul National University College of Medicine, Seoul, Korea 3 Department of Urology, Seoul National University Boramae Hospital, Seoul, Korea 4 Department of Urology, Seoul Veterans Hospital, Seoul, Korea 6 Department of Urology, Yeungnam University College of Medicine, Daegu, Korea 5 Department of Urology, Inha University College of Medicine, Incheon, Korea 1 Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea |
| AuthorAffiliation_xml | – name: 5 Department of Urology, Inha University College of Medicine, Incheon, Korea – name: 6 Department of Urology, Yeungnam University College of Medicine, Daegu, Korea – name: 4 Department of Urology, Seoul Veterans Hospital, Seoul, Korea – name: 2 Department of Urology, Seoul National University College of Medicine, Seoul, Korea – name: 1 Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea – name: 3 Department of Urology, Seoul National University Boramae Hospital, Seoul, Korea |
| Author_xml | – sequence: 1 givenname: Kun Suk surname: Kim fullname: Kim, Kun Suk organization: Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea – sequence: 2 givenname: Ji-Yoon surname: Kim fullname: Kim, Ji-Yoon organization: Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea – sequence: 3 givenname: In Gab surname: Jeong fullname: Jeong, In Gab organization: Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea – sequence: 4 givenname: Jae-Seung surname: Paick fullname: Paick, Jae-Seung organization: Department of Urology, Seoul National University College of Medicine, Seoul, Korea – sequence: 5 givenname: Hwancheol surname: Son fullname: Son, Hwancheol organization: Department of Urology, Seoul National University Boramae Hospital, Seoul, Korea – sequence: 6 givenname: Dae Jung surname: Lim fullname: Lim, Dae Jung organization: Department of Urology, Seoul National University Boramae Hospital, Seoul, Korea – sequence: 7 givenname: Hong Bang surname: Shim fullname: Shim, Hong Bang organization: Department of Urology, Seoul Veterans Hospital, Seoul, Korea – sequence: 8 givenname: Won Hee surname: Park fullname: Park, Won Hee organization: Department of Urology, Inha University College of Medicine, Incheon, Korea – sequence: 9 givenname: Hee Chang surname: Jung fullname: Jung, Hee Chang organization: Department of Urology, Yeungnam University College of Medicine, Daegu, Korea – sequence: 10 givenname: Myung-Soo surname: Choo fullname: Choo, Myung-Soo organization: Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20191044$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001423343$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNqNUctu1DAUjVARfcAPsEDe0U0GP_PYII1GQ6lURFUNa8txbog7SRxspyXf0J_GYcpzgVj52j6Pe-85TY4GO0CSvCR4xRjP3tzue7-iOF6pWLEVZ-JJckJEWaQZE_lRrDEhaVEyfpycen-LMRWCsmfJcSSVBHN-kjys0bWzfgQdzB2gD1MXTKphCODQzhnVIdugrdctOKNbo5C2nUHbr8EpHVBjHQotLBJjO3fxyehIAxX6KLFQr1UwsfTo3oQWbVpnB6NV183oBvTk3ALbzD6YYPzz5GmjOg8vHs-z5NO77W7zPr36eHG5WV-lmjMe0hpDRSsCRU2KvMElJkpQwFUjClqXIEqSxR3QgvCal9Bktc5JKQQHlleMFpSdJecH3cE1cq-NtMp8Pz9buXdyfbO7lCLnlPIIZQfoNIxqvo-Ny9GZXrlZEiyXFOSSglxSkFRIJmMKkfX2wBqnqod6WadTv5iL3Z8_g2mj-Z2M3WU5K6PA60cBZ79M4IPsjdfQdWoAO3mZs-hC8pJE5KvfrX56_Eg4AooDQMeYvYNGahNiKHZxNt2_x6B_Uf9j9m_g_M-A |
| CitedBy_id | crossref_primary_10_3390_ijms241310537 crossref_primary_10_1016_j_rmclc_2018_02_010 crossref_primary_10_13066_kspm_2018_13_1_89 crossref_primary_10_14777_uti_2017_12_1_7 crossref_primary_10_1016_j_molimm_2019_02_007 crossref_primary_10_3390_microorganisms11020344 crossref_primary_10_12968_npre_2014_12_12_608 crossref_primary_10_1016_j_mucimm_2022_12_003 crossref_primary_10_3947_ic_2012_44_5_343 crossref_primary_10_1016_j_purol_2013_09_002 crossref_primary_10_21518_2079_701X_2021_4_129_134 crossref_primary_10_1080_14656566_2020_1795128 crossref_primary_10_1016_S1995_7645_10_60159_9 crossref_primary_10_1080_09638288_2019_1670272 crossref_primary_10_1586_14787210_2015_991717 crossref_primary_10_1586_erv_12_36 crossref_primary_10_2174_0113852728322510240711045944 crossref_primary_10_1080_19490976_2024_2359691 |
| Cites_doi | 10.3109/08923978909082140 10.1016/0002-9343(82)90534-4 10.1136/bmj.298.6677.856 10.1159/000475363 10.1111/j.1464-410X.1990.tb14649.x 10.1016/S0022-5347(17)40157-1 10.3109/08923978809041425 10.1159/000281253 10.1016/S0011-393X(96)80055-5 10.1016/S0022-5347(17)35648-3 10.1136/bmj.298.6677.853 10.1016/j.ijantimicag.2007.07.018 10.1016/S0022-5347(05)64145-6 10.1056/NEJM199102283240906 10.4111/kju.2007.48.4.428 10.1016/S0891-5520(05)70378-0 10.1001/jama.1994.03510340041031 |
| ContentType | Journal Article |
| Copyright | 2010 The Korean Academy of Medical Sciences. 2010 |
| Copyright_xml | – notice: 2010 The Korean Academy of Medical Sciences. 2010 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ADTOC UNPAY ACYCR |
| DOI | 10.3346/jkms.2010.25.3.435 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall Korean Citation Index |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1598-6357 |
| EndPage | 439 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_574224 10.3346/jkms.2010.25.3.435 PMC2826739 20191044 10_3346_jkms_2010_25_3_435 |
| Genre | Clinical Trial Multicenter Study Journal Article |
| GroupedDBID | --- 29K 2WC 3O- 5-W 53G 5GY 8JR 8XY 9ZL AAYXX ADBBV ADRAZ AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION CS3 D-I DIK DU5 E3Z EBS EF. EJD F5P FRP GROUPED_DOAJ GX1 HYE KQ8 M48 O5R O5S OK1 OVT PGMZT RNS RPM TR2 W2D XSB CGR CUY CVF ECM EIF NPM 7X8 5PM ADTOC UNPAY ACYCR |
| ID | FETCH-LOGICAL-c434t-d0eb2b1e8d187f0901a52e0bf582d9e59165982814d49ef6dc719554e37b32823 |
| IEDL.DBID | M48 |
| ISSN | 1011-8934 1598-6357 |
| IngestDate | Sun Mar 09 07:51:05 EDT 2025 Tue Aug 19 22:27:09 EDT 2025 Tue Sep 30 15:59:34 EDT 2025 Fri Jul 11 15:39:46 EDT 2025 Mon Jul 21 05:59:12 EDT 2025 Tue Jul 01 01:44:44 EDT 2025 Thu Apr 24 23:02:56 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | OM-8930 Immunization Prevention and Control Escherichia coli Cystitis |
| Language | English |
| License | http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. cc-by-nc |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c434t-d0eb2b1e8d187f0901a52e0bf582d9e59165982814d49ef6dc719554e37b32823 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 G704-000345.2010.25.3.012 http://kmbase.medric.or.kr/Main.aspx?d=KMBASE&m=VIEW&i=0191120100250030435 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3346/jkms.2010.25.3.435 |
| PMID | 20191044 |
| PQID | 733531791 |
| PQPubID | 23479 |
| PageCount | 5 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_574224 unpaywall_primary_10_3346_jkms_2010_25_3_435 pubmedcentral_primary_oai_pubmedcentral_nih_gov_2826739 proquest_miscellaneous_733531791 pubmed_primary_20191044 crossref_citationtrail_10_3346_jkms_2010_25_3_435 crossref_primary_10_3346_jkms_2010_25_3_435 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2010-03-01 |
| PublicationDateYYYYMMDD | 2010-03-01 |
| PublicationDate_xml | – month: 03 year: 2010 text: 2010-03-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | Journal of Korean medical science |
| PublicationTitleAlternate | J Korean Med Sci |
| PublicationYear | 2010 |
| Publisher | The Korean Academy of Medical Sciences 대한의학회 |
| Publisher_xml | – name: The Korean Academy of Medical Sciences – name: 대한의학회 |
| References | Bottex (10.3346/jkms.2010.25.3.435_ref18) 1988; 4 Avorn (10.3346/jkms.2010.25.3.435_ref3) 1994; 271 Nicolle (10.3346/jkms.2010.25.3.435_ref4) 1997; 11 Lee (10.3346/jkms.2010.25.3.435_ref22) 2007; 48 Wybran (10.3346/jkms.2010.25.3.435_ref8) 1989; 11 Hansson (10.3346/jkms.2010.25.3.435_ref6) 1989; 298 Frey (10.3346/jkms.2010.25.3.435_ref12) 1986; 41 Ha (10.3346/jkms.2010.25.3.435_ref23) 2008; 31 Krieger (10.3346/jkms.2010.25.3.435_ref2) 2002; 168 Hauser (10.3346/jkms.2010.25.3.435_ref16) 1982; 72 Jacoby (10.3346/jkms.2010.25.3.435_ref17) 1991; 324 Tammen (10.3346/jkms.2010.25.3.435_ref15) 1988; 28 Baier (10.3346/jkms.2010.25.3.435_ref19) 1997; 47 Van Pham (10.3346/jkms.2010.25.3.435_ref9) 1990; 9 Sotolongo (10.3346/jkms.2010.25.3.435_ref7) 1990; 143 Barnett (10.3346/jkms.2010.25.3.435_ref1) 1997; 314 Schulman (10.3346/jkms.2010.25.3.435_ref14) 1993; 150 Lettgen (10.3346/jkms.2010.25.3.435_ref21) 1996; 57 Hansson (10.3346/jkms.2010.25.3.435_ref5) 1989; 298 Magasi (10.3346/jkms.2010.25.3.435_ref13) 1994; 26 Bosch (10.3346/jkms.2010.25.3.435_ref10) 1988; 10 Tammen (10.3346/jkms.2010.25.3.435_ref11) 1990; 65 Nauck (10.3346/jkms.2010.25.3.435_ref20) 1991; 4 9296288 - Arzneimittelforschung. 1997 Aug;47(8):980-5 17913471 - Int J Antimicrob Agents. 2008 Feb;31 Suppl 1:S63-7 2329615 - J Urol. 1990 May;143(5):979-80 2160522 - J Biol Response Mod. 1990 Apr;9(2):231-40 12441917 - J Urol. 2002 Dec;168(6):2351-8 3547993 - Urol Int. 1986;41(6):444-6 7044118 - Am J Med. 1982 May;72(5):711-6 9378928 - Infect Dis Clin North Am. 1997 Sep;11(3):647-62 8093138 - JAMA. 1994 Mar 9;271(10):751-4 9332263 - Am J Med Sci. 1997 Oct;314(4):245-9 2503554 - Immunopharmacol Immunotoxicol. 1989;11(1):17-32 2497823 - BMJ. 1989 Apr 1;298(6677):856-9 1992321 - N Engl J Med. 1991 Feb 28;324(9):601-12 7957468 - Eur Urol. 1994;26(2):137-40 8345609 - J Urol. 1993 Sep;150(3):917-21 2497822 - BMJ. 1989 Apr 1;298(6677):853-5 2178724 - Br J Urol. 1990 Jan;65(1):6-9 3143754 - Immunopharmacol Immunotoxicol. 1988;10(3):333-43 |
| References_xml | – volume: 11 start-page: 17 year: 1989 ident: 10.3346/jkms.2010.25.3.435_ref8 publication-title: Immunopharmacol Immunotoxicol doi: 10.3109/08923978909082140 – volume: 72 start-page: 711 year: 1982 ident: 10.3346/jkms.2010.25.3.435_ref16 publication-title: Am J Med doi: 10.1016/0002-9343(82)90534-4 – volume: 9 start-page: 231 year: 1990 ident: 10.3346/jkms.2010.25.3.435_ref9 publication-title: J Biol Response Mod – volume: 314 start-page: 245 year: 1997 ident: 10.3346/jkms.2010.25.3.435_ref1 publication-title: Am J Med Sci – volume: 298 start-page: 856 year: 1989 ident: 10.3346/jkms.2010.25.3.435_ref6 publication-title: BMJ doi: 10.1136/bmj.298.6677.856 – volume: 26 start-page: 137 year: 1994 ident: 10.3346/jkms.2010.25.3.435_ref13 publication-title: Eur Urol doi: 10.1159/000475363 – volume: 4 start-page: 203 year: 1988 ident: 10.3346/jkms.2010.25.3.435_ref18 publication-title: Int J Immunother – volume: 65 start-page: 6 year: 1990 ident: 10.3346/jkms.2010.25.3.435_ref11 publication-title: Br J Urol doi: 10.1111/j.1464-410X.1990.tb14649.x – volume: 143 start-page: 979 year: 1990 ident: 10.3346/jkms.2010.25.3.435_ref7 publication-title: J Urol doi: 10.1016/S0022-5347(17)40157-1 – volume: 10 start-page: 333 year: 1988 ident: 10.3346/jkms.2010.25.3.435_ref10 publication-title: Immunopharmacol Immunotoxicol doi: 10.3109/08923978809041425 – volume: 41 start-page: 444 year: 1986 ident: 10.3346/jkms.2010.25.3.435_ref12 publication-title: Urol Int doi: 10.1159/000281253 – volume: 47 start-page: 980 year: 1997 ident: 10.3346/jkms.2010.25.3.435_ref19 publication-title: Arzneimittelforschung – volume: 4 start-page: 1 year: 1991 ident: 10.3346/jkms.2010.25.3.435_ref20 publication-title: Int J Exp Clin Chemoter – volume: 57 start-page: 464 year: 1996 ident: 10.3346/jkms.2010.25.3.435_ref21 publication-title: Curr Ther Res doi: 10.1016/S0011-393X(96)80055-5 – volume: 150 start-page: 917 year: 1993 ident: 10.3346/jkms.2010.25.3.435_ref14 publication-title: J Urol doi: 10.1016/S0022-5347(17)35648-3 – volume: 28 start-page: 294 year: 1988 ident: 10.3346/jkms.2010.25.3.435_ref15 publication-title: Urologe B – volume: 298 start-page: 853 year: 1989 ident: 10.3346/jkms.2010.25.3.435_ref5 publication-title: BMJ doi: 10.1136/bmj.298.6677.853 – volume: 31 start-page: S63 issue: Suppl 1 year: 2008 ident: 10.3346/jkms.2010.25.3.435_ref23 publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2007.07.018 – volume: 168 start-page: 2351 year: 2002 ident: 10.3346/jkms.2010.25.3.435_ref2 publication-title: J Urol doi: 10.1016/S0022-5347(05)64145-6 – volume: 324 start-page: 601 year: 1991 ident: 10.3346/jkms.2010.25.3.435_ref17 publication-title: N Engl J Med doi: 10.1056/NEJM199102283240906 – volume: 48 start-page: 428 year: 2007 ident: 10.3346/jkms.2010.25.3.435_ref22 publication-title: Korean J Urol doi: 10.4111/kju.2007.48.4.428 – volume: 11 start-page: 647 year: 1997 ident: 10.3346/jkms.2010.25.3.435_ref4 publication-title: Infect Dis Clin North Am doi: 10.1016/S0891-5520(05)70378-0 – volume: 271 start-page: 751 year: 1994 ident: 10.3346/jkms.2010.25.3.435_ref3 publication-title: JAMA doi: 10.1001/jama.1994.03510340041031 – reference: 12441917 - J Urol. 2002 Dec;168(6):2351-8 – reference: 2329615 - J Urol. 1990 May;143(5):979-80 – reference: 3143754 - Immunopharmacol Immunotoxicol. 1988;10(3):333-43 – reference: 2160522 - J Biol Response Mod. 1990 Apr;9(2):231-40 – reference: 8093138 - JAMA. 1994 Mar 9;271(10):751-4 – reference: 8345609 - J Urol. 1993 Sep;150(3):917-21 – reference: 2497822 - BMJ. 1989 Apr 1;298(6677):853-5 – reference: 2503554 - Immunopharmacol Immunotoxicol. 1989;11(1):17-32 – reference: 9378928 - Infect Dis Clin North Am. 1997 Sep;11(3):647-62 – reference: 9332263 - Am J Med Sci. 1997 Oct;314(4):245-9 – reference: 2178724 - Br J Urol. 1990 Jan;65(1):6-9 – reference: 7044118 - Am J Med. 1982 May;72(5):711-6 – reference: 9296288 - Arzneimittelforschung. 1997 Aug;47(8):980-5 – reference: 3547993 - Urol Int. 1986;41(6):444-6 – reference: 1992321 - N Engl J Med. 1991 Feb 28;324(9):601-12 – reference: 17913471 - Int J Antimicrob Agents. 2008 Feb;31 Suppl 1:S63-7 – reference: 2497823 - BMJ. 1989 Apr 1;298(6677):856-9 – reference: 7957468 - Eur Urol. 1994;26(2):137-40 |
| SSID | ssj0025523 |
| Score | 1.9981512 |
| Snippet | We have assessed the efficacy and safety of Escherichia coli extract (ECE; Uro-Vaxom) which contains active immunostimulating fractions, in the prophylactic... We have assessed the efficacy and safety of Escherichia coli extract (ECE; Uro-Vaxom®) which contains active immunostimulating fractions, in the prophylactic... We have assessed the efficacy and safety of Escherichia coli extract (ECE; Uro-Vaxom ) which contains active immunostimulating fractions, in the prophylactic... |
| SourceID | nrf unpaywall pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 435 |
| SubjectTerms | Adult Aged Cell Extracts - immunology Cell Extracts - therapeutic use Cystitis - drug therapy Cystitis - immunology Cystitis - microbiology Cystitis - prevention & control Escherichia coli - chemistry Escherichia coli - immunology Escherichia coli - pathogenicity Female Humans Middle Aged Original Prospective Studies Recurrence 의학일반 |
| Title | A Prospective Multi-center Trial of Escherichia coli Extract for the Prophylactic Treatment of Patients with Chronically Recurrent Cystitis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/20191044 https://www.proquest.com/docview/733531791 https://pubmed.ncbi.nlm.nih.gov/PMC2826739 http://jkms.org/Synapse/Data/PDFData/0063JKMS/jkms-25-435.pdf https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001423343 |
| UnpaywallVersion | publishedVersion |
| Volume | 25 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Journal of Korean Medical Science, 2010, 25(3), 136, pp.435-439 |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1598-6357 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025523 issn: 1011-8934 databaseCode: KQ8 dateStart: 19860101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1598-6357 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025523 issn: 1011-8934 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1598-6357 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025523 issn: 1011-8934 databaseCode: DIK dateStart: 19860101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1598-6357 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025523 issn: 1011-8934 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVERR databaseName: KoreaMed Open Access customDbUrl: eissn: 1598-6357 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025523 issn: 1011-8934 databaseCode: 5-W dateStart: 19860101 isFulltext: true titleUrlDefault: https://koreamed.org/journals providerName: Korean Association of Medical Journal Editors – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1598-6357 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025523 issn: 1011-8934 databaseCode: RPM dateStart: 19860101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVFZP databaseName: Scholars Portal Open Access Journals customDbUrl: eissn: 1598-6357 dateEnd: 20250831 omitProxy: true ssIdentifier: ssj0025523 issn: 1011-8934 databaseCode: M48 dateStart: 19860901 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB61RQIuiDfhsTISN8gqiZ04OSBUoVYtaDmxUm-W49gQbciWZFewv4E_zUxeYkWLOEVKYifxjOPvs8ffALwKQ5enLg18aZCiCFtwP9c69PGcdoW2LnI0ob_4lJwtxYeL-OIAxnRHQwO2V1I7yie1bKr5z--7d9jh3xLj5LRCufrW9kFaUTzncwQAh3ADR6aIvHwhplUFRM8R7zfOXFOOpIER8yBFEXvj1GHduKsg6N-RlLe29aXe_dBV9ccwdXoX7gz4kh33DnEPDmx9H24uhhX0B_DrmGH94_5K1sUT-lSvbViXwYOtHTtpyZQlhUEzdJSS4R-cdlMxRLgMESNVgeapug1WbIpVp6KDTmvLaIKXmV56F99zxxqa2SctKGZ2FKBQtg9heXry-f2ZPyRk8I3gYuMXAfLwPLRpEabSBQgldBzZIHdxGhWZjRFqkh5gGopCZNYlhZFhhnjFcplz5Hb8ERzV69o-ARZFgQ2MkKmwsUisQZaTWK0z7RB_ZkHgQTg2vzKDWjklzagUshayniLrKbKeimLFFVrPg9dTmcteq-Ofd79Eq6qVKRVJbNPxy1qtGoVE4lzFUiC48YCNNlfY7WgtRdd2vW2V5Bz_XjILPXjcu8D0yNGDPJB7zjHdQI_bv1KXXztlb2yjRPLMgzeTG_3Hlzy99hWewe0-2oFi5p7D0abZ2hcIojb5DOnD-cdZNwUx63rJb_JcHiw |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+prospective+multi-center+trial+of+Escherichia+coli+extract+for+the+prophylactic+treatment+of+patients+with+chronically+recurrent+cystitis&rft.jtitle=Journal+of+Korean+medical+science&rft.au=Kim%2C+Kun+Suk&rft.au=Kim%2C+Ji-Yoon&rft.au=Jeong%2C+In+Gab&rft.au=Paick%2C+Jae-Seung&rft.date=2010-03-01&rft.eissn=1598-6357&rft.volume=25&rft.issue=3&rft.spage=435&rft_id=info:doi/10.3346%2Fjkms.2010.25.3.435&rft_id=info%3Apmid%2F20191044&rft.externalDocID=20191044 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1011-8934&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1011-8934&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1011-8934&client=summon |